A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

NCT01100944 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

26

Enrollment

NIH

Sponsor class

Stopped Principal investigator left the National Institutes of Health (NIH).

Conditions

Thymoma
Thymic Carcinoma

Interventions

DRUG: PXD101with cisplatin+doxorubicin+cyclophosphamide

Sponsor

National Cancer Institute (NCI)